Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy

@inproceedings{Moyle2016RetFI,
  title={Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy},
  author={Louise Anne Moyle and Eric Blanc and Oihane Jaka and Johanna Prueller and Christopher R. S. Banerji and Francesco Saverio Tedesco and Stephen D R Harridge and Robert D Knight and Peter S Zammit},
  booktitle={eLife},
  year={2016}
}
Facioscapulohumeral muscular dystrophy (FSHD) involves sporadic expression of DUX4, which inhibits myogenesis and is pro-apoptotic. To identify target genes, we over-expressed DUX4 in myoblasts and found that the receptor tyrosine kinase Ret was significantly up-regulated, suggesting a role in FSHD. RET is dynamically expressed during myogenic progression in mouse and human myoblasts. Constitutive expression of either RET9 or RET51 increased myoblast proliferation, whereas siRNA-mediated… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 130 REFERENCES

DUX4 primarily acts as a transcriptional activator, inhibiting myogenesis by inducing a less differentiated transcriptome

P Knopp, YD Krom, +5 authors PS. Zammit
  • Journal of Cell Science 129:3816–3831
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…